Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) Equity Ratio (2021 - 2025)

Roivant Sciences' Equity Ratio history spans 5 years, with the latest figure at 0.82 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 14.51% year-over-year to 0.82; the TTM value through Dec 2025 reached 0.82, down 14.51%, while the annual FY2025 figure was 0.86, 3.43% down from the prior year.
  • Equity Ratio reached 0.82 in Q4 2025 per ROIV's latest filing, down from 0.95 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.96 in Q2 2025 to a low of 0.62 in Q2 2023.
  • Average Equity Ratio over 5 years is 0.8, with a median of 0.8 recorded in 2021.
  • Peak YoY movement for Equity Ratio: decreased 19.3% in 2022, then soared 45.33% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.8 in 2021, then dropped by 19.3% to 0.65 in 2022, then skyrocketed by 38.99% to 0.9 in 2023, then rose by 6.14% to 0.96 in 2024, then fell by 14.51% to 0.82 in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Equity Ratio are 0.82 (Q4 2025), 0.95 (Q3 2025), and 0.96 (Q2 2025).